Microglia Gone Awry: Linking Immunometabolism to Neurodegeneration.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic concepts without primary clinical data
PubMed 32903682 · doi:10.3389/fncel.2020.00246
What was done
Narrative mini-review synthesizing published literature on microglial immunometabolism, aging-associated microglial activation, bioenergetic alterations, and their contribution to neurodegenerative diseases, focusing on phenotypes and regulatory checkpoint genes such as Trem2 and granulin (GRN).
What was found
The abstract reports no quantitative metrics or empirical measurements. Qualitatively, it reports that dysfunctional microglia exhibit mitochondrial deficits, elevated glycolysis, and lipid droplet accumulation, which associate with reduced phagocytosis and migration, alongside increased proinflammatory cytokine secretion and reactive oxygen species release. Checkpoint regulators including Trem2 and GRN are described as central to maintaining this metabolic fitness.
Why it matters
This review highlights microglial bioenergetic failure as an active driver of neurodegeneration rather than a passive bystander effect, pointing to immunometabolic checkpoint pathways as prospective therapeutic targets.
Limits
This is a narrative review presenting qualitative mechanistic frameworks rather than original experimental data or systematic evidence synthesis. The abstract provides no quantitative data, sample sizes, or clinical evidence demonstrating target efficacy in humans.
Cited by
- supports Destructive M1 microglia downregulate mitochondrial function and primarily rely on glycolysis for energy production.